Navigation Links
Public session of the Cancer Drug Development Roundtable at Ohio State
Date:4/25/2011

The Ohio State University Comprehensive Cancer CenterArthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) and Friends of Cancer Research (Friends) are convening a high-level group of stakeholders to discuss current obstacles halting co-development of two or more experimental drugs for the treatment of cancer.

In December 2010, the U.S. Food and Drug Administration (FDA) released a Guidance Document addressing the protocol researchers should follow when deciding if co-developing drugs is appropriate. However, barriers found outside of clinics and labs, such as business, legal, liability and intellectual property issues were not examined in detail.

The objective of the Cancer Drug Development Roundtable is to develop a set of recommendations for the FDA to be revealed later this year, addressing industry hurdles currently halting co-development, with the ultimate goal of easing the process and bringing revolutionary cancer treatments to patients faster and with more efficiency.

Prior to the closed working session occurring later in the day, Roundtable participants will hold an open public session for researchers, advocates, patients and media that would like to learn more about the issue and ask questions. Panel participants include:

  • Michael Caligiuri, M.D. - Director of The Ohio State Comprehensive Cancer Center and CEO of the James Cancer Hospital and Solove Research Institute
  • Jim Doroshow, M.D. - Director of the Division of Cancer Treatment and Diagnosis at the National Cancer Institute
  • Eric Rubin, M.D. - Vice President, Oncology Clinical Research, Merck
  • Ellen Sigal, Ph.D. - Chair and Founder, Friends of Cancer Research
  • Janet Woodcock, M.D. - Director, Center for Drug Evaluation and Research, FDA

WHERE: The Ohio State University, Biomedical Research Tower, Room 115, 460 W. 12th Avenue, Columbus, OH 43210

For those unable to attend in person, the Public Session will also be made available via Webcast and teleconference (Please RSVP to lbryan@spectrumscience.com for dial-in information and link).

WHEN: Wednesday, May 4, 2011
10:00 11:00 a.m.

WHO: Hosted by Ohio State University Comprehensive Cancer CenterArthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) and Friends of Cancer Research (Friends)


'/>"/>

Contact: Eileen Scahill
Eileen.Scahill@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. The private sale of drugs in public hospitals
2. Governor Rendell Proposes Budget With No Tax Increase, More Money for Public Schools, Strategy for Jobs, Plan to Address Future Deficits
3. Republicans Give Top Award to Betsy McCaughey, Healthcare Patriot, & Rev Up for Upcoming Elections
4. Global Health Defined as Public Health in a New Lancet Commentary by the Association of Schools of Public Health (ASPH)
5. Labopharm announces pricing of US$20 million public offering of units
6. 5W Public Relations Adds Halo/Air Salt Rooms to Its Health & Wellness Client Roster
7. Trade Privacy LLC: Research Concludes Apple Inc. Has Blocked Their Import Records from Public Access
8. BCS Global Launches PSVN (Public Switched Video Network), an Initiative to Provide a Framework for Inter-Connecting Business to Business Video Networks
9. Labopharm announces closing of US$20 million public offering of units
10. Registered Nurses from Public Health - Seattle & King County Hold Informational Picket to Highlight Public Safety Concerns
11. AADR awards the 2010 Jack Hein Public Service Award to David C. Johnsen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... India , June 24, 2016 ... Needles Market by Type (Standard Pen Needles, Safety Pen ... Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, ... by MarketsandMarkets, This report studies the market for the ... expected to reach USD 2.81 Billion by 2021 from ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
Breaking Medicine Technology: